| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Atossa Therapeutics, Inc. (ATOS) has 9 insiders with recent SEC Form 4 filings, including 6 buys and 0 sells. ATOS is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CFO | 543.8K | $3.05M | - | |
| CEO | 339.1K | $1.90M | - | |
| Dir | 125.0K | $700.0K | - | |
| Dir | 125.0K | $700.0K | - | |
| Dir | 125.0K | $700.0K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Mar 9, 2016 | Chen Shu-Chih | Director, 10% Owner | Buy | 15,000 | $0.37 | $5,550.00 | +0.3% | |
| Feb 16, 2016 | Chen Shu-Chih | Director, 10% Owner | Buy | 15,000 | $0.53 | $7,950.00 | +0.3% | |
| Feb 16, 2016 | Quay Steven C | President &CEO | Buy | 15,000 | $0.53 | $7,950.00 | +0.3% | |
| Jan 19, 2016 | Quay Steven C | President &CEO | Buy | 50,000 | $0.20 | $10,000.00 | +1.1% | |
| Jan 19, 2016 | Chen Shu-Chih | Director, 10% Owner | Buy | 50,000 | $0.20 | $10,000.00 | +1.2% | |
| Jun 12, 2015 | Remmel H. Lawrence | Director | Buy | 5,400 | $1.30 | $7,020.00 | +135.0% |